%0 Journal Article
%T Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.
%A Forrest SJ
%A Gupta H
%A Ward A
%A Li YY
%A Doan D
%A Al-Ibraheemi A
%A Alexandrescu S
%A Bandopadhayay P
%A Shusterman S
%A Mullen EA
%A Collins NB
%A Chi SN
%A Wright KD
%A Kumari P
%A Mazor T
%A Ligon KL
%A Shivdasani P
%A Manam M
%A MacConaill LE
%A Ceca E
%A Benich SN
%A London WB
%A Schilsky RL
%A Bruinooge SS
%A Guidry Auvil JM
%A Cerami E
%A Rollins BJ
%A Meyerson ML
%A Lindeman NI
%A Johnson BE
%A Cherniak AD
%A Church AJ
%A Janeway KA
%J Nat Commun
%V 15
%N 1
%D 2024 Jul 11
%M 38992034
%F 17.694
%R 10.1038/s41467-024-49944-0
%X To inform clinical trial design and real-world precision pediatric oncology practice, we classified diagnoses, assessed the landscape of mutations, and identified genomic variants matching trials in a large unselected institutional cohort of solid tumors patients sequenced at Dana-Farber / Boston Children's Cancer and Blood Disorders Center. Tumors were sequenced with OncoPanel, a targeted next-generation DNA sequencing panel. Diagnoses were classified according to the International Classification of Diseases for Oncology (ICD-O-3.2). Over 6.5 years, 888 pediatric cancer patients with 95 distinct diagnoses had successful tumor sequencing. Overall, 33% (n = 289/888) of patients had at least 1 variant matching a precision oncology trial protocol, and 14% (41/289) were treated with molecularly targeted therapy. This study highlights opportunities to use genomic data from hospital-based sequencing performed either for research or clinical care to inform ongoing and future precision oncology clinical trials. Furthermore, the study results emphasize the importance of data sharing to define the genomic landscape and targeted treatment opportunities for the large group of rare pediatric cancers we encounter in clinical practice.